Edwards Lifesciences Corporation
One Edwards Way · Irvine, CA USA · 92614
Phone: 949.250.2500 · Fax: 949.250.2525

Media Contact:  Sarah Huoh, 949-250-5070
Investor Contact:  David K. Erickson, 949-250-6826
IRVINE, Calif., February 1, 2018 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended December 31, 2017.
Fourth Quarter and Full Year Highlights:
Sales grew 16 percent in the fourth quarter and the full year
Fourth quarter global THVT sales grew 20 percent; underlying1 sales increased 22 percent
Fourth quarter EPS declined 77 percent driven by special charges related to U.S. tax reform;
adjusted EPS grew 25 percent
Full year 2017 EPS grew 10 percent; adjusted EPS grew 31 percent
Increased 2018 sales and earnings guidance
“We are pleased to report robust fourth quarter results including double-digit organic revenue growth in each region. Our company finished the quarter and year strong, both at 16 percent sales growth,” said Michael A. Mussallem, chairman and CEO. “Our strong 2017 growth was driven by clinician and patient preferences for our innovative and meaningful therapies. Profitability was also strong in 2017, with adjusted EPS growing over 30 percent, even as we continued to invest aggressively in our technology pipeline and infrastructure.”
Fourth Quarter 2017 Results
Sales for the quarter ended December 31, 2017 were $888.5 million, up 15.7 percent. Total adjusted sales were $909.4 million, up 15.9 percent over the fourth quarter last year. Net income for the quarter ended December 31, 2017 was $35.7 million, or $0.17 per share. Adjusted EPS grew 25.3 percent to $0.94.
For the quarter, the company reported Transcatheter Heart Valve Therapy (THVT) sales of $519.3 million, a 20.2 percent growth rate over the fourth quarter last year. Adjusted THVT sales were $540.2 million, up 22.0 percent on an underlying basis, including the adjustment for the consumption of stocking inventory in Germany. Double-digit underlying TAVR sales growth across all regions was driven by continued strong therapy adoption.


The following information was filed by Edwards Lifesciences Corp (EW) on Thursday, February 1, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Edwards Lifesciences Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Edwards Lifesciences Corp.


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Log in with your credentials


Forgot your details?

Create Account